What is a stock summary page? Click here for an overview.
Business Description
Barinthus Biotherapeutics PLC
ISIN : US91864C1071
Share Class Description:
BRNS: ADRDescription
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 9.22 | |||||
| Equity-to-Asset | 0.81 | |||||
| Debt-to-Equity | 0.09 | |||||
| Debt-to-EBITDA | -0.22 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -1.58 | |||||
| Beneish M-Score | 11.72 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 236.2 | |||||
| 3-Year EBITDA Growth Rate | 8.7 | |||||
| 3-Year EPS without NRI Growth Rate | 9.4 | |||||
| 3-Year FCF Growth Rate | 16.5 | |||||
| 3-Year Book Growth Rate | -21.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -18.02 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 54.33 | |||||
| 9-Day RSI | 52.42 | |||||
| 14-Day RSI | 51.26 | |||||
| 3-1 Month Momentum % | -12.57 | |||||
| 6-1 Month Momentum % | -19.13 | |||||
| 12-1 Month Momentum % | -59.73 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.03 | |||||
| Quick Ratio | 8.03 | |||||
| Cash Ratio | 7.07 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.7 | |||||
| Shareholder Yield % | -6.08 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -345.9 | |||||
| Net Margin % | -408 | |||||
| FCF Margin % | -199.29 | |||||
| ROE % | -37.96 | |||||
| ROA % | -32.15 | |||||
| ROIC % | -87.14 | |||||
| 3-Year ROIIC % | 59.31 | |||||
| ROC (Joel Greenblatt) % | -353.57 | |||||
| ROCE % | -34.84 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.67 | |||||
| PB Ratio | 0.33 | |||||
| Price-to-Tangible-Book | 0.39 | |||||
| EV-to-EBIT | 0.94 | |||||
| EV-to-EBITDA | 1.03 | |||||
| EV-to-Revenue | -3.82 | |||||
| EV-to-Forward-Revenue | 14.21 | |||||
| EV-to-FCF | 1.91 | |||||
| Price-to-GF-Value | 0.36 | |||||
| Price-to-Net-Current-Asset-Value | 0.45 | |||||
| Price-to-Net-Cash | 0.53 | |||||
| Earnings Yield (Greenblatt) % | 106.38 | |||||
| FCF Yield % | -69.77 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BRNS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Barinthus Biotherapeutics PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 14.969 | ||
| EPS (TTM) ($) | -1.55 | ||
| Beta | -1.02 | ||
| 3-Year Sharpe Ratio | -0.6 | ||
| 3-Year Sortino Ratio | -0.84 | ||
| Volatility % | 60.54 | ||
| 14-Day RSI | 51.26 | ||
| 14-Day ATR ($) | 0.088848 | ||
| 20-Day SMA ($) | 1.004998 | ||
| 12-1 Month Momentum % | -59.73 | ||
| 52-Week Range ($) | 0.8008 - 4.1591 | ||
| Shares Outstanding (Mil) | 40.34 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Barinthus Biotherapeutics PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Barinthus Biotherapeutics PLC Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Barinthus Biotherapeutics PLC Frequently Asked Questions
What is Barinthus Biotherapeutics PLC(BRNS)'s stock price today?
The current price of BRNS is $1.06. The 52 week high of BRNS is $4.16 and 52 week low is $0.80.
When is next earnings date of Barinthus Biotherapeutics PLC(BRNS)?
The next earnings date of Barinthus Biotherapeutics PLC(BRNS) is 2025-05-13 Est..
Does Barinthus Biotherapeutics PLC(BRNS) pay dividends? If so, how much?
Barinthus Biotherapeutics PLC(BRNS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers